The vaccine, Cyfendus, is approved for use after suspected or confirmed exposure to Bacillus anthracis, also known as anthrax, but must be administered together with other antibacterial drugs.

Dr. Meryl Nass, bioterrorism and anthrax expert, told The Defender she is skeptical about whether the vaccine offers any new substantive health benefit.

“Given the history of the company’s many failures, and the lack of proper safety or efficacy testing of prior anthrax vaccines, one can only expect problems,” Nass said.

“The fact that there is no label available, there is no information on how it was tested, what placebo was used, et cetera — that all adds to the consternation and concern people should have about the value of this product,” Nass added.

https://childrenshealthdefense.org/defender/fda-approves-cyfendus-anthrax-vaccine-adults/?